An observational study in Rheumatoid Arthritis (RA), sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Arthritis, Rheumatoid by Assiut University — 22 open to participants now, 22 under way, none of them phase 3. Arthritis, Rheumatoid · Assiut University.
Among the 49 studies in Arthritis, Rheumatoid by Assiut University, this one is the 6th largest by planned enrollment of the 43 observational ones that give a count, is one of 10 that started in 2026, is one of 43 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 44th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →22 of the 49 studies in Arthritis, Rheumatoid by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18–50
Assiut University
Ages 18+
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2026.
This study's planned enrollment of 120 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 90 across the 6 interventional studies, 80 across the 43 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
9 of the studies in Arthritis, Rheumatoid by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07761767Assiut UniversitySelf-Care Education for Joint Stiffness and Functional Ability in Rheumatoid Arthritis | 2027-01-01 |
| NCT07129837Assiut UniversitySerum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients. | 2027-03 |
| NCT07657156Assiut UniversityMusculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis | 2027-07 |
| NCT07105566Assiut UniversityTriosephosphate Isomerase Level in Relation to Rheumatoid Aerthritis Activity and Structural Damage | 2027-09 |
| NCT07810569Assiut UniversityOcular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients | 2027-10 |
Add all 9 to your calendar (.ics) → With an account.
Among the 49 studies in Arthritis, Rheumatoid by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate QT dispersion, P-wave dispersion and Tp-e dispersion as predictors of cardiac arrhythmias in patients with rheumatoid arthritis and to assess their relationship with disease characteristics and inflammatory activity
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by persistent synovial inflammation and progressive joint destruction. In addition to musculoskeletal manifestations, patients with RA have an increased risk of cardiovascular morbidity and mortality compared with the general population. Cardiac arrhythmias represent one of the important cardiovascular complications in these patients and may contribute to sudden cardiac death Electrocardiographic markers reflecting abnormalities in atrial and ventricular depolarization and repolarization have gained increasing attention as predictors of arrhythmogenic risk. QT dispersion (QTd) reflects heterogeneity of ventricular repolarization and has been associated with ventricular arrhythmias. P-wave dispersion (PWD) represents inhomogeneous atrial conduction and is considered a predictor of atrial arrhythmias, particularly atrial fibrillation. Tp-e interval and Tp-e dispersion are relatively newer markers reflecting transmural dispersion of ventricular repolarization and have been linked to malignant ventricular arrhythmias Chronic inflammation, autonomic dysfunction, endothelial dysfunction and myocardial involvement in rheumatoid arthritis may contribute to abnormalities in these electrocardiographic parameters. Early identification of patients at higher risk of cardiac arrhythmias may improve risk stratification and allow timely intervention. Therefore, the present study aims to evaluate QT dispersion, P-wave dispersion and Tp-e dispersion as predictors of cardiac arrhythmias in patients with rheumatoid arthritis
adult male and female participants aged ≥18 years, including patients with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria and age- and sex matched healthy controls. Participants with other autoimmune diseases, thyroid disorders, cardiac diseases, electrolyte abnormalities (hypocalcemia, hypokalemia, or hypomagnesemia), or use of drugs known to affect cardiac rhythm such as amiodarone will be excluded
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rheumatoid arthritis patients diagnosed according to 2010 ACR\\EULAR criteria
healthy controls without RA meeting study eligibility criteria
QT dispersion, P-wave dispersion and Tp-e dispersion
to assess QT dispersion , P wave dispersion and Tp-e dispersion on 12 lead ECG and compare their values between rheumatoid arthritis patients and healthy controls and to evaluate their association with the risk of cardiac arrhythmia
Time frame: baseline
Correlation between ECG parameters and disease activity assessed by DAS28
to evaluate the correlation between QT dispersion P wave dispersion Tp-e dispersion with rheumatoid arthritis disease activity assessed by DAS28
Time frame: at baseline
No study locations are listed for this record.
Plan to share: No
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 12 months is below that.
Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.